The first challenge in drug discovery is selecting a biological target and validating it as a ‘druggable’ binding site. The key to this is identifying several potent compounds that can be used in more advanced validating assays. To achieve this go/no-go point, good chemical starting points need to be found and then compounds are optimised for binding.

 

In this webinar hosted by DDW, Curia shares its findings that protein X-ray crystallography is essential to accelerate the design process by providing a level of structural detail unmatched by computational methods.

 

The speakers will describe how Curia’s team designed a new protein construct that provided the first crystal structure of Artemis, an unproven target blocking DNA-repair in oncology.